Where Will Vertex Pharmaceuticals Be in 10 Years?
Vertex Pharmaceuticals (NASDAQ: VRTX) has come a long way in the past ten years. In a little over a decade, the company has built a cystic fibrosis (CF) empire, commercializing four drugs for the disease that together generate blockbuster revenue . And the share price has soared more than 400%, scoring a big win for long-term investors.
Now, whether you're a Vertex investor or a potential one, you may be wondering what's next for this big biotech. The company recently started its expansion beyond CF with a U.K. regulatory nod for exa-cel, a gene-editing treatment for blood disorders. And Vertex has several candidates across treatment areas in the pipeline. Where will the company be in 10 years? Let's find out.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Vertex Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 440 € für Vertex Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 422.25 €.
